Clinical Trials
215 trialsRABBIT
University of Arizona
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
TRANSCEND-XR
Gustave Roussy, Cancer Campus, Grand Paris
Digital Peer Navigation for Adolescents and Young Adults With Cancer
University Health Network, Toronto
LIAM Mc
University College Cork
VITALSS
UNC Lineberger Comprehensive Cancer Center
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech SE
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
EFICATEST
University of Malaga
STARTER
Centre Leon Berard
TESTIGO
Sahlgrenska University Hospital
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
TG-BIL
University Hospital, Clermont-Ferrand
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
RPLND
Indiana University
PERSIST
Indiana University
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
PRESERVE
Loma Linda University
ASPIRE
Wake Forest University Health Sciences
AYA STEPS
Duke University
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
SWENOTECA-ABC
St. Olavs Hospital
TASTY-steering
University Medical Center Groningen
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
AYAConnect
UNC Lineberger Comprehensive Cancer Center
EARN
Washington University School of Medicine
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
RPLND-Seminoma
Western University, Canada
AVENTURINE
BioNTech SE
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
University of California, Irvine
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Testicular Self-Examination Awareness in Young Men
Hitit University
Low-Dose CT - Stage I Testicular Cancer
University Health Network, Toronto
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
UNICANCER
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Fudan University
Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
University Medical Center Groningen
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
M.D. Anderson Cancer Center
WATChmAN Virtual Testicular Cancer Clinic
University Health Network, Toronto
Short-term Testosterone Replacement in Testicular Cancer Survivors
University Medical Center Groningen
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
MV
Royal Marsden NHS Foundation Trust
TASTY
University Medical Center Groningen
GAMEC-II
Queen Mary University of London